NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
11/01/2022
Back to search
Official data from USPTO
NEOFORDEX
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
15
Latest update
11/01/2022
Trademark type
Word
Nice classes
5
Filing date
09/29/2021
Registration date
11/01/2022
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
11/01/2022
Last transaction
11/01/2022
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Drawing code
4
Owner type
99
Owner location
Boulogne-Billancourt, FR
Examiner
ENGEL, MICHAEL
Law office
L70
Current location
PUBLICATION AND ISSUE SECTION
Holders and representatives
Holders
L. C. (pessoa física)
Representatives
Pina Campagna CARTER, DELUCA & FARRELL LLP
Technical classification
Nice Classes
Class 5
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Pharmaceutical and veterinary products for treating progression of chronic diseasesproliferative diseasesfor treating rheumatological diseases; pharmaceutical and veterinary products for treating oncological diseasescolon cancerrectum cancerbreast cancerprostate cancerpancreatic cancergastric cancerthyroid cancerlarynx cancerliver canceruterine cancercervical canceresophagus cancerovarian cancerlung cancerpleural canceroral cavity cancerkidney cancerbladder cancertesticular cancermelanomalymphatic cancerhematopoietic cancercarcinomasarcomanervous system cancerprimary tumors; pharmaceutical and veterinary products for treating onco-haematological diseaseslymphomasHodgkin's disease and non-Hodgkin lymphomaslymphadenopathymyelomamultiple myelomaleukemia; pharmaceutical and veterinary products for treating haematological diseasesamylosespurpurathrombocytopenic purpura; pillscapsulestabletspowders pertaining to healthy diet for use in treating oncological diseases; chemical preparations for medical and pharmaceutical use for treating progression of chronic diseasesproliferative diseasefor treating rheumatological diseases; chemical preparations for medical and pharmaceutical use for treating oncological diseasescolon cancerrectum cancerbreast cancerprostate cancerpancreatic cancergastric cancerthyroid cancerlarynx cancerliver canceruterine cancercervical canceresophagus cancerovarian cancerlung cancerpleural canceroral cavity cancerkidney cancerbladder cancertesticular cancermelanomalymphatic cancerhematopoietic cancercarcinomasarcomanervous system cancerprimary tumors; chemical preparations for medical and pharmaceutical use for treating onco-haematological diseaseslymphomasHodgkin's disease and non-Hodgkin lymphomaslymphadenopathymyelomamultiple myelomaleukemia. chemical preparations for medical and pharmaceutical use for treating haematological diseasesamylosespurpuraespecially thrombocytopenic purpura
Publications
History of USPTO decisions and trademark events.
15 publications found
R.PR
REGISTERED-PRINCIPAL REGISTER
11/01/2022
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
08/16/2022
PUBO
PUBLISHED FOR OPPOSITION
08/16/2022
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
07/27/2022
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
07/14/2022
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
07/13/2022
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
07/12/2022
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
07/12/2022
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
07/05/2022
GNRT
NON-FINAL ACTION E-MAILED
07/05/2022
CNRT
NON-FINAL ACTION WRITTEN
07/05/2022
DOCK
ASSIGNED TO EXAMINER
06/29/2022
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
10/27/2021
NWAP
NEW APPLICATION ENTERED
10/02/2021
Continuous trademark protection
Get notified about every new filing that threatens NEOFORDEX or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.